Checkpoint Agrees To Sun Pharma Buyout

Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. | Takeda is sharpening its oncology focus amid an R&D revamp.
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and targeted oncology company, for $355 million. The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through several acquisitions and collaborations.
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
India's pharma giant Sun Pharma to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment of $355M. The deal involves an upfront cash payment of $4.
Sun Pharma to Acquire Checkpoint Therapeutics
(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company.
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLOXCYT,
Fierce Pharma4d
On the heels of FDA nod for cancer drug, Sun Pharma buys Checkpoint Therapeutics for up to $416M
Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
Checkpoint Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Checkpoint Therapeutics (CKPT) to Neutral from Buy with a price target of $4.10, down from $20, following the ...
HC Wainwright Reaffirms Neutral Rating for Checkpoint Therapeutics (NASDAQ:CKPT)
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC ...
Labiotech.eu2d
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Checkpoint price target lowered to $4.80 from $9 at D. Boral Capital
D. Boral Capital lowered the firm’s price target on Checkpoint Therapeutics (CKPT) to $4.80 from $9 and keeps a Buy rating on the shares. The ...
Checkpoint Therapeutics’ (CKPT) Hold Rating Reaffirmed at Lake Street Capital
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...